Oxurion Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Pascal Ghoson

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Feb 01

CEO

Pascal Ghoson

less than a year

Permanencia

Mr. Pascal Ghoson is Director of Quantum Genomics Société Anonyme from 2024. Mr. Pascal Ghoson is Administrative & Financial Director of SA Energisme from May 2023. He serves as a Director of Hopium SA sin...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pascal Ghoson	CEO, CFO & Executive Director	less than a year	sin datos	sin datos
James Hartmann	Independent Non-Executive Director	less than a year	sin datos	sin datos
Charles de Bollardiere	Independent Chairman of the Board	less than a year	sin datos	sin datos
Nathalie Laarakker	Non-Executive	1.7yrs	€34.92k	sin datos
Anat Loewenstein	Non-Executive	1.7yrs	€26.92k	sin datos

0.9yrs

Permanencia media

Junta con experiencia: La junta directiva de OXUR no se considera experimentada (0.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Oxurion Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Oxurion NV, Annual General Meeting, May 07, 2024

Oxurion Announces CEO Changes

High number of new and inexperienced directors

Less than half of directors are independent

Oxurion NV, Annual General Meeting, May 02, 2023

Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer

Recent updates

First half 2024 earnings released

Oxurion NV (ENXTBR:OXUR) signed a letter of intent to acquire 80% stake in Contract Research Organisation for €9.8 million.

Full year 2023 earnings released: €0.01 loss per share (vs €0.37 loss in FY 2022)

New minor risk - Financial data availability

Oxurion NV to Report Fiscal Year 2023 Results on Apr 15, 2024

Oxurion NV, Annual General Meeting, May 07, 2024

Oxurion Announces CEO Changes

Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

First half 2023 earnings released: €0.02 loss per share (vs €0.32 loss in 1H 2022)

Oxurion NV to Report First Half, 2023 Results on Sep 29, 2023

Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema

High number of new and inexperienced directors

Less than half of directors are independent

Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis

Oxurion NV Announces Interim Analysis for KALAHARI Trial

Price target decreased to €1.25

Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022

Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

Price target increased to €10.00

Oxurion NV, Annual General Meeting, May 02, 2023

Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Oxurion NV Announces New Data on THR-149 Phase 2 Clinical Trial in DME At the Angiogenesis, Exudation, and Degeneration 2022 Conference

Oxurion Provides Update on Clinical Pipeline Progress

Oxurion NV announced that it has received €10 million in funding from Pontifax Ltd., Kreos Capital Management (UK) Limited

OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Full year 2020 earnings released

Oxurion NV announced that it expects to receive €30 million in funding from Negma Group Ltd.

Full year 2020 earnings released: €0.75 loss per share (vs €1.35 loss in FY 2019)

Oxurion NV to Report Fiscal Year 2020 Final Results on Apr 05, 2021

What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer

How Is Oxurion's (EBR:OXUR) CEO Compensated?

New 90-day high: €2.90

Oxurion NV to Report Fiscal Year 2021 Results on Mar 17, 2022

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Oxurion NV Announces Executive Changes

Baron Philippe Vlerick, Non-Executive member of the Board of ThromboGenics NV acquired 3.6% stake in ThromboGenics NV (ENXTBR:THR).

New 90-day low: €2.45

Oxurion NV(ENXTBR:OXUR) dropped from S&P Global BMI Index

First half earnings released

Here's What We Learned About The CEO Pay At Oxurion NV (EBR:OXUR)

New 90-day low - €2.57

Oxurion (EBR:OXUR) Share Prices Have Dropped 43% In The Last Year

CEO

Permanencia

Miembros de la Junta

Permanencia media